Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1, SINGLE DOSE OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF LORLATINIB IN SUBJECTS WITH IMPAIRED RENAL FUNCTION

NCT03542305 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03542305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03542305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1, SINGLE DOSE OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF LORLATINIB IN SUBJECTS WITH IMPAIRED RENAL FUNCTION
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2018
Completion date
February 20, 2020
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment